Brief: Silk Road Medical Announces First Patient Enrolled In Roadster 3 Post Approval Study Evaluating Tcar® System In The Treatment Of Standard Surgical Risk Patients
07/09/2022 22:15
Sept 7 (Reuters) - Silk Road Medical Inc SILK.O :
* SILK ROAD MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN
ROADSTER 3
POST APPROVAL STUDY EVALUATING TCAR® SYSTEM IN THE TREATMENT OF
STANDARD SURGICAL RISK PATIENTS
Source text for Eikon: ID:nGNX16nkNf
Further company coverage: SILK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silk Road Medical
See all newsBrief: Silk Road Medical Boston Scientific To Be Required To Pay Co Termination Fee Of $69.5 Million If Merger Agreement Terminated Under Certain Circumstances
Boston Scientific to buy Silk Road Medical in $1.16 billion deal (updated)
Brief: Boston Scientific Announces Agreement to Acquire Silk Road Medical
Brief: Silk Road Medical Announces Definitive Agreement To Be Acquired By Boston Scientific
Boston Scientific to buy Silk Road Medical for $1.16 billion